To date, three different approaches targeting MUC1 (mAbs, vaccines and small peptide inhibitors of MUC1 cytoplasmic domain) have been developed and are in different phases of clinical trials for the treatment of human cancers, including breast cancers. The gene discussed is MUC1; the disease is breast carcinoma.